A practical reference on Metabolite: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-30 and is reviewed periodically as new material appears.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Early work on the study of the chemistry of rutherfordium focused on gas thermochromatography and measurement of relative deposition temperature adsorption curves. The initial work was carried out at Dubna in an attempt to reaffirm their discovery of the element. Recent work is more reliable regarding the identification of the parent rutherfordium radioisotopes. The isotope 261mRf has been used for these studies, though the long-lived 267Rf (produced in the decay chain of 291Lv, 287Fl, and 283Cn) may be advantageous for future experiments. The experiments relied on the expectation that rutherfordium would be a 6d element in group 4 and should therefore form a volatile molecular tetrachloride, that would be tetrahedral in shape. Rutherfordium(IV) chloride is more volatile than its lighter homologue hafnium(IV) chloride (HfCl4) because its bonds are more covalent. A series of experiments confirmed that rutherfordium behaves as a typical member of group 4, forming a tetravalent chloride (RfCl4) and bromide (RfBr4) as well as an oxychloride (RfOCl2). A decreased volatility was observed for RfCl4 when potassium chloride is provided as the solid phase instead of gas, highly indicative of the formation of nonvolatile K2RfCl6 mixed salt.
Production process – it can be derived from biotechnology or from other technologies. It may be prepared using more conventional techniques as is the case for blood or plasma-derived products and a number of vaccines. Active substance – consisting of entire microorganisms, mammalian cells, nucleic acids, proteinaceous, or polysaccharide components originating from a microbial, animal, human, or plant source. Mode of action – therapeutic and immunological medicinal products, gene transfer materials, or cell therapy materials.
(2026) make the name of the toxodontid Andinotoxodon bolivarensis, originally described in a doctoral dissertation, available under the International Code of Zoological Nomenclature. The first confirmed fossil material of Late Pleistocene Toxodon platensis from the San Luis Province (Argentina), providing information on the intracranial anatomy of members of this species, is described from the Barranquita Formation by Hernández Del Pino et al. (2026). Evidence from the study of tooth wear of Tremacyllus and Paedotherium, interpreted as indicating that pachyrukhine hegetotheriid notoungulates were mainly fruit-seed consumers rather than grazers, is presented by Armella & Croft (2026). A study on the evolution of the morphological similarity to molar teeth in premolar teeth of ungulates, based on data from extant and extinct artiodactyls and perissodactyls, is published by Ashbaugh, Jamniczky & Theodor (2026). A study on tooth wear of early Pleistocene ungulates from the Quibas site (Murcia, Spain), interpreted as indicative of a broad spectrum of feeding behaviours consistent with presence of mosaic environments including grasslands with wooded patches, is published by Ramírez-Pedraza, Agustí & Piñero (2026). Hussain et al. (2026) reconstruct the dietary presences of Pleistocene ungulates from the Pinjor Formation (Pakistan) on the basis of the study of their tooth wear, interpreted as indicating that the studied assemblage was dominated by grazers but also included browsers and mixed-feeders.
Sources: en.wikipedia.org
== Transplanted human organoids == Bio- and electrical engineers have shown that human cerebral organoids transplanted into mice functionally integrate with their visual cortex. Such models may raise similar ethical issues as organoid-based humanization of other animals.
Reaction between tin tetrachloride and sulfuric acid in a 1:2 molar mixture at near reflux (114 °C): SnCl4 + 2 H2SO4 → Sn(SO4)2 + 4 HCl Pyrolysis of anhydrous tin(IV) sulfate at 150 °C - 200 °C: Sn(SO4)2 → SnO2 + 2 SO3 To further reduce water contamination, Oleum and a slight excess of Tin(IV) Chloride should be used. The slight excess of SnCl4 can then be separated by carefully heating the solid Tin(IV) Sulfate under a vacuum to no more than 120 °C. The excess SO3 from the Oleum and the remaining SnCl4 will react during HCl formation and form Tin(IV) Oxide and Sulfuryl Chloride. If an excess of SO3 in the Oleum is present relative to SnCl4 , the Tin(IV) Oxide will absorb it and form more Tin(IV) Sulfate. The advantage of this method over the sodium bisulfate one is that it can produce the pure trimer of SO3 (since no water is present) while still using safe temperatures for normal borosilicate laboratory glassware. Other dry sulfate salt pyrolysis reactions require higher temperatures which increases the risk of shattering. A disadvantage is that it generates significant quantities of hydrogen chloride gas which needs to be captured as well. SO3 may also be prepared by dehydrating sulfuric acid with phosphorus pentoxide.
=== Genomic maintenance === Proliferating cell nuclear antigen (PCNA) is a protein involved in DNA synthesis. Under normal physiological conditions PCNA is sumoylated (a similar post-translational modification to ubiquitylation). When DNA is damaged by ultra-violet radiation or chemicals, the SUMO molecule that is attached to a lysine residue is replaced by ubiquitin. Monoubiquitylated PCNA recruits polymerases that can carry out DNA synthesis with damaged DNA; but this is very error-prone, possibly resulting in the synthesis of mutated DNA. Lysine 63-linked polyubiquitylation of PCNA allows it to perform a less error-prone mutation bypass known by the template switching pathway. Ubiquitylation of histone H2AX is involved in DNA damage recognition of DNA double-strand breaks. Lysine 63-linked polyubiquitin chains are formed on H2AX histone by the E2/E3 ligase pair, Ubc13-Mms2/RNF168. This K63 chain appears to recruit RAP80, which contains a UIM, and RAP80 then helps localize BRCA1. This pathway will eventually recruit the necessary proteins for homologous recombination repair.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.